Ocular Therapeutix Inc. (NASDAQ:OCUL) traded up 32.1% during mid-day trading on Thursday . The stock traded as high as $5.73 and last traded at $5.55, with a volume of 4,716,489 shares trading hands. The stock had previously closed at $4.20.

Several equities research analysts recently issued reports on the company. BTIG Research reiterated a “buy” rating and issued a $18.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, July 26th. Cowen and Company reiterated a “buy” rating on shares of Ocular Therapeutix in a research note on Monday, June 6th. Morgan Stanley reiterated an “overweight” rating and issued a $16.00 price target (down from $17.00) on shares of Ocular Therapeutix in a research note on Tuesday, June 7th. Zacks Investment Research cut Ocular Therapeutix from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $48.00 price target on shares of Ocular Therapeutix in a research note on Sunday, April 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Ocular Therapeutix presently has an average rating of “Buy” and an average target price of $22.81.

The firm has a 50 day moving average of $5.06 and a 200-day moving average of $8.21. The firm’s market capitalization is $160.24 million.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.01. The business had revenue of $458 million for the quarter. On average, equities analysts anticipate that Ocular Therapeutix Inc. will post ($1.86) EPS for the current fiscal year.

In related news, CEO Amarpreet Sawhney purchased 10,000 shares of the firm’s stock in a transaction dated Thursday, June 9th. The stock was bought at an average price of $6.70 per share, for a total transaction of $67,000.00. Following the purchase, the chief executive officer now directly owns 573,733 shares in the company, valued at approximately $3,844,011.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.